Forbes September 5, 2024
At least two in five U.S. adults — or more than 57 million people – under the age of 65 with “private insurance could be eligible under clinical criteria for GLP-1 drugs,” a new analysis shows.
KFF, formerly known as the Kaiser Family Foundation, said that 42% of U.S. adults could be covered by health insurers if they are treated for “type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis.
“Though only about 3% of adults with employer coverage had a prescription in 2022, demand for and spending on GLP-1 drugs has grown and could continue to grow,” KFF said in its analysis. “Given the steep costs and high demand for these...
Today's Sponsors
Today's Sponsor